Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22475
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
dc.contributor.author | Chuo-Shih Chen | en |
dc.contributor.author | 陳卓士 | zh_TW |
dc.date.accessioned | 2021-06-08T04:18:39Z | - |
dc.date.copyright | 2010-09-09 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-07-27 | |
dc.identifier.citation | 1. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
2. Torbenson M, Thomas DL. Occult hepatitis B. The Lancet Infectious Diseases 2002;2:479-486. 3. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. Journal of Hepatology 2007;46:160-170. 4. Bayram A, Erkilic S, Ozkur A, Bayram M, Sari I. Quantification of intrahepatic total hepatitis B virus DNA in chronic hepatitis B patients and its relationship with liver histology. J Clin Pathol 2008;61:338-342. 5. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-272. 6. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, Risk Evaluation of Viral Load E, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. 7. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-546. 8. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001;34:194-203. 9. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Valdes A, Galimany R, et al. Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. J Viral Hepat 2001;8:465-471. 10. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-2901. 11. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659-666. 12. Laperche S, Thibault V, Bouchardeau F, Alain S, Castelain S, Gassin M, Gueudin M, et al. Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol 2006;44:3600-3607. 13. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004;39:51-57. 14. Cabrerizo M, Bartolome J, De Sequera P, Caramelo C, Carreno V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997;8:1443-1447. 15. Altindis M, Uslan I, Cetinkaya Z, Yuksel S, Ciftci IH, Demirturk N, Ozdemir M, et al. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B]. Mikrobiyol Bul 2007;41:227-233. 16. Drago L, Lombardi A, De Vecchi E, Giuliani G, Bartolone R, Gismondo M. Comparison of nested PCR and real time PCR of Herpesvirus infections of central nervous system in HIV patients. BMC Infectious Diseases 2004;4:55. 17. Kawada J, Kimura H, Ito Y, Hoshino Y, Tanaka-Kitajima N, Ando Y, Futamura M, et al. Comparison of real-time and nested PCR assays for detection of herpes simplex virus DNA. Microbiol Immunol 2004;48:411-415. 18. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26. 19. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102-110. 20. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004;127:1356-1371. 21. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000;174:98-111. 22. De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: Molecular oncogenic potential of clear or occult infections. European Journal of Cancer 2010;In Press, Corrected Proof. 23. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-1108. 24. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127:S56-61. 25. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008;134:1470-1481. 26. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68. 27. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-1016. 28. Weinberger KM, Bauer T, Bohm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000;81:1165-1174. 29. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194:594-599. 30. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24 Suppl 1:3-10. 31. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130:823-837. 32. Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M. Comprehensive Genetic and Epigenetic Analysis of Occult Hepatitis B from Liver Tissue Samples. Clinical Infectious Diseases 2008;46:1227-1236. 33. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002;37:855-862. 34. Wang JT, Lee CZ, Chen PJ, Wang TH, Chen DS. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 2002;42:1592-1597. 35. Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991;163:397-399. 36. Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, Wang JH, et al. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009;125:621-629. 37. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-4071. 38. Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, Chan FK, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol 2002;97:1211-1215. 39. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006;106:1326-1330. 40. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005;34 Suppl 1:S15-21. 41. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006;36 Suppl 1:S33-44. 42. Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, Suzuki F, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009;16:437-443. 43. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172-1179. 44. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531-1537. 45. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-1199. 46. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-1701. 47. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50. 48. Kalendar R LD, Schulman AH. FastPCR Software for PCR Primer and Probe Design and Repeat Search. Genes, Genomes and Genomics 2009;3(1):1-14 [http://primerdigital.com/fastpcr.html]. 49. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599. 50. Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, Chang WY, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991;13:398-406. 51. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-308. 52. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127:S72-78. 53. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669. 54. Koay LB, Lin CY, Tsai SL, Lee C, Lin CN, Sheu MJ, Kuo HT, et al. Type 1 autoimmune hepatitis in Taiwan: diagnosis using the revised criteria of the International Autoimmune Hepatitis Group. Dig Dis Sci 2006;51:1978-1984. 55. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-423. 56. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-731. 57. Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, Chen CJ. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 2008;26:5576-5582. 58. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Bartolome J, Pardo M, Carreno V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. J Med Virol 2007;79:236-241. 59. Carreno V, Bartolome J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008;18:139-157. 60. De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D, Panico S, et al. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One 2009;4:e8128. 61. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148-155. 62. Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, Zhao HW, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009;58:383-388. 63. Villa E, Grottola A, Buttafoco P, Trande P, Merighi A, Fratti N, Seium Y, et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci 1995;40:8-13. 64. Takeuchi M, Fujimoto J, Niwamoto H, Yamamoto Y, Okamoto E. Frequent detection of hepatitis B virus X-gene DNA in hepatocellular carcinoma and adjacent liver tissue in hepatitis B surface antigen-negative patients. Dig Dis Sci 1997;42:2264-2269. 65. Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S, Arakawa Y, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008;51:352-361. 66. Schuttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000;355:41-42. 67. Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, Wang SH, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003;278:591-607. 68. Chang HC, Yu MW, Lu CF, Chiu YH, Chen CJ. Risk factors associated with hepatitis C virus infection in Taiwanese government employees. Epidemiol Infect 2001;126:291-299. 69. Farza H, Salmon AM, Hadchouel M, Moreau JL, Babinet C, Tiollais P, Pourcel C. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci U S A 1987;84:1187-1191. 70. Ganem D. Persistent infection of humans with hepatitis B virus: mechanisms and consequences. Rev Infect Dis 1982;4:1026-1047. 71. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356-1361. 72. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-1164. 73. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286:533-535. 74. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469. 75. Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, Lui WY, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int 2005;25:236-241. 76. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-259. 77. Huang J, Li BK, Chen GH, Li JQ, Zhang YQ, Li GH, Yuan YF. Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. J Gastrointest Surg 2009;13:1627-1635. 78. Tangkijvanich P, Mahachai V, Suwangool P, Poovorawan Y. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol 2004;10:1547-1550. 79. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-1944. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22475 | - |
dc.description.abstract | 研究背景和目的
B型肝炎隱性感染可能會導致肝細胞癌發生。本研究針對肝細胞癌進行病例系列研究,探討:1) B型肝炎隱性感染在non-B病例中的盛行率;2)B型肝炎隱性感染病例之特徵及和病因的關係;3) B型肝炎隱性感染和臨床表徵及存活的關係。 材料與方法 研究個案包括420名HBsAg陰性的肝細胞癌病例,依照anti-HCV狀態、酒精攝取,將研究個案區分成不同病因組。採用nested-PCR方法檢測HBV surface (S)及X基因區病毒DNA。 結果 HBV DNA 在S、X、及S且X區陽性率,各為21.4%、11.0%、和15.2%。anti-HCV陽性者與陰性者相比,其B型肝炎隱性感染率顯著偏低(P=0.01),男性之隱性感染率高於女性(P=0.0374)。進入醫院時的血清α-fetoprotein(AFP)、腫瘤大小和B型肝炎隱性感染呈現正相關。但在控制其他危險因子及進入醫院之臨床特徵之後,並未發現HBV DNA陽性和存活有關。 結論 non-B、non-C病例及男性有較高的B型肝炎隱性感染率,且B型肝炎隱性感染和較高的AFP及較大的腫瘤有關。 | zh_TW |
dc.description.abstract | Background & Aims:
Occult hepatitis B virus (HBV) infection has been implicated in the etiology of hepatocellular carcinoma (HCC). The specific aims of this study were to 1) estimate the prevalence of occult HBV infection in major etiological groups of HCC patients, 2) identify factors associated with occult HBV infection in HCC patients, and 3) assess the association of occult HBV infection with clinical features at hospital admission and survival. Methods: Study subjects included 420 hepatitis B surface antigen-negative HCC patients. They were grouped into different classes according to the status of antibodies against hepatitis C virus (anti-HCV) and the intensity and duration of alcohol consumption. We detected HBV DNA in circulation by a nested-polymerase chain reaction with primers designed based on the sequences of the surface(S) and X regions of HBV. Results: Overall, 90 (21.4%) patients were positive for HBs DNA, 46 (11.0%) tested positive for HBx DNA, and 64 (15.2%) tested positive for both HBs DNA and HBx DNA. While anti-HCV positive patients had a lower prevalence of occult HBV infection than anti-HCV negative patients (P=0.01), males had a higher prevalence than females (P=0.0374). Serum α-fetoprotein levels and tumor size were positively correlated with occult HBV infection. However, we failed to detect a significant association between occult HBV infection and survival after adjustment for potential prognostic factors. Conclusions: Occult HBV infection was more frequently detected in non-B, non-C HCC patients than in HBsAg-negative, anti-HCV-positive patients with HCC, and was more prevalent in male HCC patients than in female HCC patients. This infection may be associated with a more severe stage of HCC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:18:39Z (GMT). No. of bitstreams: 1 ntu-99-R97842022-1.pdf: 948651 bytes, checksum: b1eae04c98027615b72bd5b1e0b5331c (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員會審定書....................................................... i
誌謝.................................................... ii 中文摘要..................................................... iii 英文摘要...................................................... iv 研究背景...................................................... 1 材料與方法...................................................... 5 研究個案...................................................... 5 實驗方法...................................................... 6 統計分析....................................... 7 結果.................................................... 8 討論.................................................... 10 參考文獻................................................ 15 圖一、樣本篩選流程表...................................................... 28 圖二、Nested-PCR偵測極限測試...................................................... 29 圖三、HBsAg陰性者其HBV S基因區增幅產物之序列分析........ 30 圖四、HBsAg陰性者其HBV X基因區增幅產物之序列分析........ 31 圖五、非B肝病毒帶原者世代族群樣本檢測................... 32 表一、研究個案分佈情形...................................................... 33 表二、Nested PCR 引子...................................................... 34 表三、不同病因之HCC病例的B型肝炎隱性感染盛行率...................................................... 35 表四、B型肝炎隱性感染之相關因子...................................................... 36 表五、B型肝炎隱性感染者進入醫院臨床特徵................. 39 表六、存活分析..................................................... 41 | |
dc.language.iso | zh-TW | |
dc.title | 隱性B型肝炎病毒感染和肝細胞癌的罹病及預後的關係 | zh_TW |
dc.title | Role of Occult Hepatitis B Virus Infection in the Etiology and Prognosis of Hepatocellular Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳肇卿,熊昭,蔡孟勳,莊雅惠 | |
dc.subject.keyword | B型肝炎隱性感染,肝細胞癌,C型肝炎病毒,酒精攝取,腫瘤大小,甲型胎兒蛋白, | zh_TW |
dc.subject.keyword | occult HBV,HCC,HCV,alcohol,tumor size,AFP, | en |
dc.relation.page | 41 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2010-07-27 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
Appears in Collections: | 流行病學與預防醫學研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-99-1.pdf Restricted Access | 926.42 kB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.